Audit: QRS - PEG-MGF for Health & Longevity

Audit conducted on 06/08/2026 10:47 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	91
Passed	82
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every protocol figure, gate item, tier item, biomarker row and cadence statement traces to the ER (Therapeutic Protocol, Key Interactions & Contraindications, Expected Benefits, Potential Risks & Side Effects, Monitoring Protocol & Defining Success, Practical Considerations, Conclusion).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“No validated protocol”, “No comparison exists”, “No timeline established for any outcome”, “no human study has been published” mirror ER lines 348, 364, 405 and 476.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain absolute; protocol values remain flagged as vendor/forum-derived in the sub cells.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER’s “Populations who should avoid this intervention” bullet; Key Interactions only from the eight interaction bullets; no modifying factors leak into either gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, author names or NCT identifiers appear. Drug names (somatropin, CJC-1295, MK-677, pegfilgrastim, etc.) all appear in the ER for the same fact.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the sheet.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Sober, sceptical register matching the ER’s own framing of an uncharacterised grey-market compound.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Presents the evidence gap plainly and gives actionable monitoring and self-assessment material rather than prohibitions.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Statements are descriptive (“Length of circulating protocols; an expectation without evidence”), not prescriptive.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives directed at a reader; the protocol panel reports what is circulating, qualified in each sub cell.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No recommending or advising verbs anywhere in the sheet.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms appear only where the ER’s own decision gates and biomarker names require them; the At-A-Glance is fully plain.
2.8	Information is presented in a concise and very compact manner	🟢	All gate, tier, marker and qualitative entries are reduced to headline facts.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Monitoring panel, qualitative trackers and product-identity risks are pitched at a self-directed, risk-aware user.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Eight-marker laboratory panel with a multi-point cadence and weekly structured self-rating assumes exactly that willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No general-population simplification; assumes access to specialist assays such as IGFBP-3 and high-sensitivity C-reactive protein.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The anti-doping and unverified-product risks are given High tier, which is the weighting relevant to this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” appears in the title; “anti-aging” appears nowhere.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Per injection, subcutaneous or intramuscular”, “hypersensitivity”, “injection-site reactions” — formal register throughout.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings and column headers are byte-identical to [qrs_template]. Tier labels present for every rendered tier.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 30 distinct template variables present; marker_#_* expanded to 1–8 and qualitative_item_# to 1–5, as intended.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff against [qrs_template] shows changes confined to the metadata block and the checklist-addressed variables; CSS, website="…" spans, footer and disclaimer unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the Benefits High/Medium tiers carry explanatory prose and are governed by item 12.5 instead.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	All five Qualitative Assessment labels and all eight Monitoring marker names are carried over verbatim from the ER.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Where an ER bullet maps to a QRS row, the label is verbatim; the Protocol and Time-to-Effect cells subdivide single ER bullets, which have no per-cell ER label to carry over.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Confirmed by scan — no emoji characters anywhere; the ER’s 🟩/🟥/🟨/⚠️ markers were stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to headline level: benefit and risk tiers are name-only lists, gate items are stripped of rationale, and biomarker why cells are single clauses.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately following <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the “QRS — Metadata” caption precedes it.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is echoed on the page except those the header legitimately renders.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, and it contains a colon; all other values are bare and trimmed.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: peg_mgf_2026-0806-0851_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge in QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0806-1007.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: peg_mgf_2026-0806-0851_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including git_user and git_issue; all clean.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“PEG-MGF for Health & Longevity - Quick Reference Sheet”, correctly entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“PEG-MGF for Health & Longevity”, matching ER frontmatter canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0806-1007 → “08/06/2026”.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only title and the template subline; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses all three Conclusion paragraphs: what the compound is, the preclinical-only evidence base, the conflicted authorship and retraction, and the sport ban plus absent supply.
7.2	[at_a_glance] is no longer than 60 words	🟢	Exactly 60 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to ER lines 476, 478 and 480 respectively.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“laboratory-made copy”, “chemical chain”, “patent-holding laboratory”, “withdrawn” — no jargon; the only acronym is the intervention’s own canonical name.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years or sample sizes appear.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric results of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items derive from the “Populations who should avoid this intervention” bullet at ER line 324.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All ten ER exclusion populations are represented, with none added or omitted.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Ten well-formed <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER glosses (“genes whose normal job is repairing damaged DNA”, “in whom growth plate and tissue development are incompletely resolved”) are stripped; no trailing dash clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	PSA threshold 4 ng/mL, CKD stage 3+/eGFR below 60 mL/min/1.73 m², age 25, cancer-before-60 window, and the named PEGylated drugs are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section; thresholds are written out in words.
8.7	If no [stop_items] are present the section is left empty	N/A	Ten stop items are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map to the eight interaction bullets at ER lines 308–322.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eight interactions carried over; no overlap with the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight well-formed <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “Severity — …”, “Consequence: …” and “Mitigating action: …” clauses are all stripped; only the bold interaction label and drug list remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every named drug list is preserved; the two supplement bullets have their examples pulled up from the ER body into parentheses.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction parentheses contain only drug-name lists, no ranking symbols.
9.7	If no [caution_items] are present the section is left empty	N/A	Eight caution items are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol section, chiefly the “circulating grey-market protocol” and “Single versus split dosing” bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, Frequency and Cycle length are the three parameters the ER itself specifies for the circulating protocol.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct actionable aspects exist and all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine fields populated; each sub carries the ER’s own qualification that the figures are unvalidated.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Captures all three elements of the ER “Time to effect” bullet (line 405): no established timeline, the 4–6 week protocol expectation, and the absence of any perceptible change.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	No benefit-linked timelines exist in the ER; the cells follow the ER’s own order of presentation within the Time to effect bullet.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects exist and all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine fields populated from ER line 405.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eight entries are the ER’s own benefit headings from the Low and Speculative tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present, with Low and Speculative populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Heading names only; the ER’s Magnitude: lines and body prose are entirely omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content carried over; the “⚠️ Conflicted” marker on the satellite-cell benefit is stripped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	benefits_high and benefits_medium are empty with style="display: none", correctly reflecting the ER’s “No benefit reaches this evidence level”.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eleven entries are the ER’s own risk headings across the four tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Heading names only; the ER’s Magnitude: lines and supporting prose are omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content carried over; the “⚠️ Conflicted” marker on Tumour-Promoting Potential is stripped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers contain items in the ER, so no span needs hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All rows derive from the biomarker table in the ER Monitoring Protocol & Defining Success section (lines 431–440).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER biomarkers present with their optimal ranges: IGF-1, IGFBP-3, prostate-specific antigen, fasting glucose and HbA1c, comprehensive metabolic panel, creatine kinase, high-sensitivity C-reactive protein, and complete blood count with differential.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Reproduces the ER cadence at lines 427–429: baseline within two weeks and after 72 hours without heavy training, repeat at 8 weeks, end of cycle, then every 6 months, with PSA additionally at 3 and 12 months.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items derive from the qualitative marker bullets at ER lines 444–452.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five present with the ER’s bold labels verbatim: training performance, recovery between sessions, resolution of minor musculoskeletal complaints, injection site condition, and energy, sleep quality and mood.

Issues 06/08/2026 10:47

Pass rate 100.00%. No issues found.

Issues 06/08/2026 10:39

1. 10.4 — Cycle-length sub sourced off-section: action_3_sub (QRS line 472) reads “Convention borrowed from anabolic steroid practice, not from the peptide.”, which is drawn from the ER Discontinuation & Cycling section (ER line 379) rather than from the ER Therapeutic Protocol section as the item requires.

Fixes 06/08/2026 10:39

1. 10.4 — Cycle-length sub sourced off-section: Replaced action_3_sub (QRS line 472) from “Convention borrowed from anabolic steroid practice, not from the peptide.” to “Not derived from any pharmacological study; no practitioner consensus grounded in outcome data.”, drawing the text from the ER Therapeutic Protocol section instead of Discontinuation & Cycling.

Issues 06/08/2026 10:33

1. 1.2 — Cautious ER phrasing dropped: Two hedges present in the ER are missing in the QRS: [time_3_sub] (line 511) says “The mechanism produces no sensation” where the ER (line 405) says “the proposed mechanism”; [at_a_glance] (line 433) says “a muscle repair fragment” where the ER Conclusion (line 476) says “a short protein fragment that muscle appears to release under heavy load”.

Fixes 06/08/2026 10:33

1. 1.2 — Restored “proposed” hedge on mechanism: [time_3_sub] changed from “The mechanism produces no sensation and no observable change.” to “The proposed mechanism produces no sensation and no observable change.”, matching the ER’s cautious phrasing.
2. 1.2 — Restored “appears to release” hedge: [at_a_glance] changed from “a muscle repair fragment” to “a fragment muscle appears to release for repair”, mirroring the ER Conclusion; “ever” and “and” were trimmed to keep the section at the 60-word limit.

Issues 06/08/2026 10:23

1. 1.1 — Garbled family-cancer contraindication: The second [stop_items] entry (QRS lines 547-549) reads “two or more first-degree cancers before 60”, but the ER (line 324) states “two or more first-degree relatives with cancer diagnosed before age 60”; the dropped “relatives with” makes the item read as a claim the ER does not support.

Fixes 06/08/2026 10:23

1. 1.1 — Garbled family-cancer contraindication: Changed the second [stop_items] entry from “two or more first-degree cancers before 60” to “two or more first-degree relatives with cancer before 60”, matching the ER wording.

Issues 06/08/2026 10:14

1. 4.5 — Sheet overflows one A4 page: At print width the sheet renders to roughly 1.9 A4 pages: the decision-gate grid alone occupies ~415px, the 8-row monitoring table ~395px, and the qualitative and protocol cells carry near-ER-length prose, against ~1033px of usable A4 height. The action_#_sub cells, contraindication and interaction entries, monitoring “Why” column and qualitative items were not condensed to the per-section budget.

Fixes 06/08/2026 10:14

1. 4.5 — Protocol and time-to-effect sub-lines condensed: Rewrote all six action_#_sub and time_#_sub cells to fragment length (e.g. “Per injection, subcutaneously or intramuscularly. No validated protocol exists; figures originate from vendor literature and bodybuilding forums.” → “Per injection, subcutaneous or intramuscular. No validated protocol; vendor and forum figures.”), removing four wrapped lines from the protocol panel.
2. 4.5 — Contraindication entries trimmed: Shortened five of the ten stop_items while keeping every threshold and parenthetical qualifier intact (e.g. “Chronic kidney disease stage 3 or worse (eGFR below 60 mL/min/1.73 m²)” → “Chronic kidney disease stage 3+ (eGFR below 60 mL/min/1.73 m²)”), cutting the stop column from 19 to 16 wrapped lines.
3. 4.5 — Interaction drug lists compressed: Trimmed the parenthetical example lists in three caution_items (sulfonylurea/meglitinide class glosses reduced to the drug names, “MK-677/ibutamoren” to “MK-677”) while leaving all eight ER bold labels verbatim.
4. 4.5 — Monitoring table condensed: Shortened all eight marker_#_why cells and the marker_5_target cell (e.g. “The single most important safety marker, given demonstrated proliferative activity in prostate cancer cells” → “Key safety marker; proliferative activity shown in prostate cancer cells”), reducing the table from roughly 20 to 14 wrapped lines.
5. 4.5 — Cadence and qualitative items tightened: Condensed monitoring_cadence and three of the five qualitative items to fragment length without dropping any interval, threshold or observation target.